• español
    • English
  • English 
    • español
    • English
  • Login
View Item 
  •   DSpace Home
  • Producción Científica
  • Artículos, capítulos, libros...UCO
  • View Item
  •   DSpace Home
  • Producción Científica
  • Artículos, capítulos, libros...UCO
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

mTOR Expression in Liver Transplant Candidates with Hepatocellular Carcinoma: Impact on Histological Features and Tumour Recurrence

Thumbnail
View/Open
ijms-20-00336.pdf (1.544Mb)
Author
Guerrero, Marta
Ferrín, Gustavo
Rodríguez-Perálvarez, Manuel
González Rubio, Sandra
Sánchez-Frías, Marina
Amado-Torres, Víctor
Pozo, Juan C.
Poyato, Antonio
Ciria, Rubén
Ayllón Terán, M. Dolores
Barrera, Pilar
Montero, José L.
Mata, Manuel de la
Publisher
MDPI
Date
2019
Subject
Liver transplantation
Hepatocellular carcinoma
mTOR
Immunosuppression
METS:
Mostrar el registro METS
PREMIS:
Mostrar el registro PREMIS
Metadata
Show full item record
Abstract
(1) Background: The mammalian target of rapamycin (mTOR) pathway activation is critical for hepatocellular carcinoma (HCC) progression. We aimed to evaluate the mTOR tissue expresión in liver transplant (LT) patients and to analyse its influence on post-LT outcomes. (2) Methods: Prospective study including a cohort of HCC patients who underwent LT (2012–2015). MTOR pathway expression was evaluated in the explanted liver by using the “PathScan Intracellular Signalling Array Kit” (Cell Signalling). Kaplan-Meier and Cox regression analyses were performed to evaluate post-LT HCC recurrence. (3) Results: Forty-nine patients were included (average age 56.4 _ 6, 14.3% females). Phospho-mTOR (Ser2448) was over-expressed in peritumoral tissue as compared with tumoral tissue (DSignal 22.2%; p < 0.001). The mTOR activators were also increased in peritumoral tissue (phospho-Akt (Thr308) DSignal 18.2%, p = 0.004; phospho-AMPKa (Thr172) DSignal 56.3%, p < 0.001), as they were the downstream effectors responsible for cell growth/survival (phospho-p70S6K (Thr389) DSignal 33.3%, p < 0.001 and phospho-S6RP (Ser235/236) DSignal 54.6%, p < 0.001). MTOR expression was increased in patients with multinodular HCC (tumoral p = 0.01; peritumoral p = 0.001). Increased phospho-mTOR in tumoral tissue was associated with higher HCC recurrence rates after LT (23.8% vs. 5.9% at 24 months, p = 0.04). (4) Conclusion: mTOR pathway is over-expressed in patients with multinodular HCC and is it associated with increased post-LT tumour recurrence rates.
URI
http://hdl.handle.net/10396/17955
Fuente
International Journal of Molecular Sciences 20(2), 336 (2019)
Versión del Editor
http://dx.doi.org/10.3390/ijms20020336
Collections
  • DMed-Artículos, capítulos...
  • Artículos, capítulos, libros...UCO

DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
© Biblioteca Universidad de Córdoba
Biblioteca  UCODigital
 

 

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

LoginRegister

Statistics

View Usage Statistics

De Interés

Archivo Delegado/AutoarchivoAyudaPolíticas de Helvia

Compartir


DSpace software copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
© Biblioteca Universidad de Córdoba
Biblioteca  UCODigital